Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) posted its earnings results on Monday. The biotechnology company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.02), Briefing.com reports. During the same period in the previous year, the business posted ($0.82) earnings per share.
Rocket Pharmaceuticals Price Performance
Shares of Rocket Pharmaceuticals stock traded down $1.23 during trading on Wednesday, hitting $18.90. 842,547 shares of the company’s stock traded hands, compared to its average volume of 757,898. The company has a debt-to-equity ratio of 0.04, a current ratio of 10.47 and a quick ratio of 10.47. The firm’s fifty day moving average price is $22.25 and its 200 day moving average price is $24.76. The company has a market cap of $1.72 billion, a PE ratio of -6.64 and a beta of 1.13. Rocket Pharmaceuticals has a twelve month low of $14.89 and a twelve month high of $32.53.
Insider Activity
In other Rocket Pharmaceuticals news, CEO Gaurav Shah sold 9,790 shares of the company’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $23.35, for a total value of $228,596.50. Following the sale, the chief executive officer now directly owns 728,069 shares in the company, valued at $17,000,411.15. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Rocket Pharmaceuticals news, CEO Gaurav Shah sold 9,790 shares of the business’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $23.35, for a total value of $228,596.50. Following the transaction, the chief executive officer now directly owns 728,069 shares in the company, valued at $17,000,411.15. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider John Militello sold 1,079 shares of the firm’s stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $23.35, for a total transaction of $25,194.65. Following the sale, the insider now directly owns 53,327 shares of the company’s stock, valued at approximately $1,245,185.45. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 15,755 shares of company stock worth $358,654. Company insiders own 31.10% of the company’s stock.
Analyst Ratings Changes
Check Out Our Latest Stock Analysis on RCKT
About Rocket Pharmaceuticals
Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.
See Also
- Five stocks we like better than Rocket Pharmaceuticals
- What Is WallStreetBets and What Stocks Are They Targeting?
- What Are Bonds? A High-Level Overview
- What Are Dividends? Buy the Best Dividend Stocks
- Super Micro Stock Drops Sharply After Earnings on Margin Concerns
- What is Short Interest? How to Use It
- Lyft’s First-Ever Profit, but the Outlook Is a Speed Bump
Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.